Back
  1. Home
  2. Profile of Aline Genbauffe (UMONS)
Profil

Genbauffe Aline

Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Service de Biologie humaine et Toxicologie

Université de Mons - UMONS > Recherche > Service de l'Institut des Sciences et Technologies de la santé

Main Referenced Co-authors
BLANKERT, Bertrand  (1)
Ghanem, Ghanem (1)
JOURNE, Fabrice  (1)
Mouchart, Lena (1)
Mukeba-Harchies, Léa (1)
Main Referenced Keywords
ATP1A1 (1); Bufalin (1); Cancer Research (1); Cardiotonic steroid (1); Genetics (1);
Main Referenced Disciplines
Oncology (1)
Chemistry (1)
Physical, chemical, mathematical & earth Sciences: Multidisciplinary, general & others (1)

Publications (total 1)

The most downloaded
16 downloads
Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y https://hdl.handle.net/20.500.12907/48079

Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y
Peer Reviewed verified by ORBi

Contact ORBi UMONS